SMMT Summit Therapeutics Inc

Summit Therapeutics plc (Nasdaq:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Mr. Glyn Edwards, Summit's Chief Executive Officer, is scheduled to present at Needham and Company's 14th Annual Healthcare Conference at 11:20am EDT (4:20pm BST) on 15th April 2015 in New York City.

A live audio webcast of the presentation, and a copy of the slides, will be available through the Investors section of Summit's website. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)	Tel: +44 (0)1235 443 951
Erik Ostrowski (US office)	+1 617 294 6607
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson	Tel: +44 (0)20 7148 7900
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer	Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications
(US media contact)	Tel: +1 781 235 3060
Michelle Avery	mavery@macbiocom.com
Peckwater PR
(Financial public relations, UK)	Tel: +44 (0)7879 458 364
Tarquin Edwards	tarquin.edwards@peckwaterpr.co.uk